Analyst Conference Summaries |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Moderna
|
2024 | |||
Moderna Q4 2023 |
Moderna Q1 2024 |
Moderna Q2 2024 |
Moderna Q3 2024 |
Feb. 22, 2024 | May 2, 2024 | Aug. 1, 2024 | Nov. 7, 2024 |
2023 | |||
Moderna Q4 2022 |
Moderna Q1 2023 |
Moderna Q2 2023 |
Moderna Q3 2023 |
Feb. 23, 2023 | May 4, 2023 | Aug. 3, 2023 | Nov. 2, 2023 |
2022 | |||
Moderna Q4 2021 |
Moderna Q1 2022 |
Moderna Q2 2022 |
Moderna Q3 2022 |
Feb. 24, 2022 | May 4, 2022 | August 3, 2022 | Nov. 3, 2022 |
2021 | |||
Moderna Q4 2020 |
Moderna Q1 2021 |
Moderna Q2 2021 |
Moderna Q3 2021 |
Feb. 25, 2021 | May 6, 2021 | Aug. 5, 2021 | Nov. 4, 2021 |
2020 | |||
Moderna Q4 2019 |
Moderna Q1 2020 |
Moderna Q2 2020 |
Moderna Q3 2020 |
Feb. 26, 2020 | May 7, 2020 | Aug. 5, 2020 | Oct. 29, 2020 |
2019 | |||
Moderna Q4 2018 |
Moderna Q1 2019 |
Moderna Q2 2019 |
Moderna Q3 2019 |
March 6, 2019 | May 8, 2019 | August 7, 2019 | Nov. 6, 2019 |
Moderna (MRNA) is a clinical-stage biotechnology company specializing in RNA based therapies.
More Analyst Conference Pages:
AGEN |
AGIO |
ALLO |
ALNY |
AMAT |
AMGN |
APRE |
ARWR |
BIIB |
BLRX |
BLUE |
BMY |
CLDX |
CDTX |
FATE |
GILD |
GLYC |
ILMN |
INO |
IONS |
MCHP |
PLX |
REGN |
RNA |
SAGE |
SANA |
SYRS |
TSVT |
VRTX |
VSTM |
WBA |
Disclaimer: My analyst summaries may include both condensations of statements made by company representatives and my own analysis. They are not covered by any warranty. I cannot guarantee anything said by company representatives is true. I try not to make errors, but it is possible. These are my personal notes which I share with other investors and which I use as the basis of my blog and Seeking Alpha articles.
Copyright 2024 William P. Meyers